Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse
NCT00373503Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Aug 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lofexidine and dronabinol in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Primary endpoint: Marijuana relapse at 4 days. Started Aug 2005; status: completed.
02
Drugs
lofexidinedronabinol
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT00373503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373503.